Telix Pharmaceuticals (NASDAQ:TLX) CEO Buys $499,560.00 in Stock

Telix Pharmaceuticals Limited (NASDAQ:TLX) CEO Christian Behrenbruch purchased 34,500 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The stock was acquired at an average price of $14.48 per share, with a total value of $499,560.00. Following the purchase, the chief executive officer directly owned 20,709,500 shares of the company’s stock, valued at approximately $299,873,560. The trade was a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Christian Behrenbruch also recently made the following trade(s):

• On Wednesday, April 29th, Christian Behrenbruch acquired 33,435 shares of Telix Pharmaceuticals stock. The shares were purchased at an average price of $14.87 per share, with a total value of $497,178.45.

Telix Pharmaceuticals Stock Performance

Telix Pharmaceuticals stock opened at $10.68 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Telix Pharmaceuticals Limited has a one year low of $6.28 and a one year high of $18.49. The stock has a fifty day moving average of $9.18 and a 200 day moving average of $8.77.

Telix Pharmaceuticals (NASDAQ:TLX) last posted its quarterly earnings data on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The company had revenue of $206.72 million during the quarter, compared to the consensus estimate of $421.50 million. Analysts forecast that Telix Pharmaceuticals Limited will post 0.09 EPS for the current fiscal year.

Institutional Trading of Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Private Advisor Group LLC lifted its position in Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after acquiring an additional 128,070 shares during the period. Vident Advisory LLC purchased a new position in shares of Telix Pharmaceuticals in the 4th quarter valued at about $204,000. XTX Topco Ltd purchased a new stake in Telix Pharmaceuticals during the 4th quarter worth approximately $89,000. Quadrature Capital Ltd purchased a new stake in Telix Pharmaceuticals during the 4th quarter worth approximately $276,000. Finally, OLD Mission Capital LLC purchased a new stake in Telix Pharmaceuticals during the 4th quarter worth approximately $111,000.

Analyst Ratings Changes

Several analysts have issued reports on the company. Citigroup boosted their price target on Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a report on Tuesday, February 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.13.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.